CRIS Current Research Information System

AUTERI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.397
NA - Nord America 2.296
EU - Europa 1.324
AF - Africa 154
Continente sconosciuto - Info sul continente non disponibili 146
SA - Sud America 139
OC - Oceania 5
Totale 6.461
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.214
SG - Singapore 658
CN - Cina 603
VN - Vietnam 577
IT - Italia 356
DE - Germania 193
SE - Svezia 165
GB - Regno Unito 158
HK - Hong Kong 149
IN - India 122
BR - Brasile 101
FR - Francia 90
KR - Corea 75
RU - Federazione Russa 63
IE - Irlanda 62
NL - Olanda 61
FI - Finlandia 57
CI - Costa d'Avorio 54
CA - Canada 51
BD - Bangladesh 35
JP - Giappone 35
TG - Togo 35
ZA - Sudafrica 23
PH - Filippine 20
TH - Thailandia 19
ID - Indonesia 18
JO - Giordania 17
BE - Belgio 16
TW - Taiwan 16
MX - Messico 15
PL - Polonia 15
BG - Bulgaria 14
CH - Svizzera 12
TR - Turchia 11
AR - Argentina 10
AT - Austria 10
NG - Nigeria 10
UA - Ucraina 10
EE - Estonia 9
PK - Pakistan 9
EC - Ecuador 8
CZ - Repubblica Ceca 7
SC - Seychelles 7
CO - Colombia 6
PY - Paraguay 6
IQ - Iraq 5
JM - Giamaica 5
LV - Lettonia 5
MA - Marocco 5
AU - Australia 4
EG - Egitto 4
ES - Italia 4
ET - Etiopia 4
IR - Iran 4
LT - Lituania 4
SA - Arabia Saudita 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AZ - Azerbaigian 3
MY - Malesia 3
PE - Perù 3
CL - Cile 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
NI - Nicaragua 2
RO - Romania 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AO - Angola 1
BB - Barbados 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
CG - Congo 1
GA - Gabon 1
GE - Georgia 1
GF - Guiana Francese 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LB - Libano 1
MG - Madagascar 1
MK - Macedonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UZ - Uzbekistan 1
Totale 6.316
Salva come PNG Salva come JPEG
Città #
Singapore 487
Ashburn 306
Chandler 197
San Jose 184
Hong Kong 139
Hanoi 137
Hefei 130
Ho Chi Minh City 121
Southend 110
Dong Ket 93
Santa Clara 88
Dallas 75
Beijing 70
Fairfield 69
Los Angeles 64
Bologna 63
Seoul 63
Dublin 62
Council Bluffs 56
Abidjan 54
Princeton 52
Milan 47
Boardman 42
Helsinki 41
New York 41
Houston 39
Lomé 35
Hyderabad 34
Munich 34
Cornaredo 32
Seattle 32
Lauterbourg 30
Wilmington 30
Woodbridge 29
Redmond 26
Cambridge 24
Tokyo 24
Ann Arbor 23
São Paulo 22
Buffalo 21
Turin 21
Clifton 20
Bremen 19
Nanjing 19
Amman 17
Da Nang 17
Haiphong 17
Brussels 16
Frankfurt am Main 16
Shanghai 16
Toronto 16
North Bergen 15
Rome 15
Berlin 14
Johannesburg 14
Sofia 14
Westminster 14
Bengaluru 13
Chicago 13
Jakarta 13
Nuremberg 13
Phoenix 13
Warsaw 12
Lappeenranta 11
London 11
Montreal 11
Piscataway 11
Manaus 10
Boydton 9
Monheim 9
Redondo Beach 9
Secaucus 9
Amsterdam 8
Bern 8
Des Moines 8
Orem 8
San Francisco 8
Abeokuta 7
Paris 7
Perugia 7
Shijiazhuang 7
Brooklyn 6
Bình Phước 6
Can Tho 6
Changsha 6
Falkenstein 6
Guangzhou 6
Medford 6
Modena 6
Newark 6
Saint Petersburg 6
Shenyang 6
Stockholm 6
Atlanta 5
Biên Hòa 5
Boston 5
Brno 5
Casalecchio di Reno 5
City of London 5
Columbus 5
Totale 3.848
Salva come PNG Salva come JPEG
Nome #
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 240
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 233
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 232
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 231
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 219
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 218
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 211
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 208
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 208
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 205
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 202
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 199
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 197
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 193
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 180
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 160
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 160
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 157
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 156
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 152
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 149
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 146
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 143
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 142
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 140
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 134
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 133
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 131
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 130
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 128
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 127
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 122
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 116
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 113
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 107
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 101
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 99
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 93
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 90
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 88
null 68
Totale 6.461
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.930
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022538 0 17 24 51 32 22 11 49 19 53 155 105
2022/2023760 56 100 45 104 62 78 15 46 137 28 57 32
2023/2024316 16 49 23 32 20 45 2 30 13 30 31 25
2024/20251.169 90 95 89 92 118 65 79 83 51 92 85 230
2025/20262.754 247 248 245 212 252 123 252 141 596 210 74 154
2026/2027315 204 111 0 0 0 0 0 0 0 0 0 0
Totale 6.461